Development and characterization of Zaleplon solid dispersion systems: A technical note

AAPS PharmSciTech

Volumn 9, Issue 2, 2008, Pages 536-543

  Waghmare, Atish ^a   Pore, Yogesh ^a   Kuchekar, Bhanudas ^a  

^a Government College of Pharmacy   (India)

Author keywords

Characterization; Crystallinity; Dissolution; Hydrophilic polymers; Solid dispersion; Zaleplon

Indexed keywords

MACROGOL 6000; POLOXAMER; POLYMER; POVIDONE; SURFACTANT; ZALEPLON; ACETAMIDE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; MACROGOL DERIVATIVE; PYRIMIDINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STRUCTURE; ENCAPSULATION; MAXIMUM PLASMA CONCENTRATION; SOLID; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM; INFRARED SPECTROSCOPY; KINETICS; METHODOLOGY; PHARMACEUTICS; POWDER DIFFRACTION; SOLUBILITY; THIN LAYER CHROMATOGRAPHY; X RAY CRYSTALLOGRAPHY;

ACETAMIDES; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, THIN LAYER; CRYSTALLOGRAPHY, X-RAY; DOSAGE FORMS; HYPNOTICS AND SEDATIVES; KINETICS; POLOXAMER; POLYETHYLENE GLYCOLS; POLYMERS; POVIDONE; POWDER DIFFRACTION; PYRIMIDINES; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL;

EID: 51449083126     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-008-9077-1     Document Type: Article

References (33)

1. M. Dooley, and G. Plosker. Zaleplon a review of its use in the treatment of insomnia. Drugs 60:413-445 (2000).
2. M. Hurst, and S. Noble. Zaleplon. CNS Drugs 11:387-392 (1999).
3. K. Damgen, and H. Luddens. Zaleplon displays a selectivity to recombinant GABA A receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci. Res. Commun. 25:139-148 (1999).
4. D. R. Drover. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives zaleplon, zolpidem and zopiclone. Clin. Pharmacokinet. 43:227-238 (2004).
5. D. Drover, H. Lemmens, S. Naidu, W. Cevallos, M. Darwish, and D. Stanski. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin. Ther. 22:1443-1461 (2000).
6. A. S. Rosen, P. Fournie, M. Darwish, P. Danjou, and S. M. Troy. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm. Drug Dispos. 20:171-175 (1999).
7. D. J. Greenblatt, J. S. Harmatz, L. L. von Moltke, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin. Pharmacol. Ther. 64:553-561 (1998).
8. RxList.com [homepage on the internet]. New York: The Internet Drug Index, Sonata Discription, WebMD, Inc.; c1996-2005, Available at http://www.rxlist.com/cgi/generic/zaleplon.htm. Accessed January 11, 2007.
9. D. Horter, and J. B. Dressman. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 25: 3-14 (1997).
10. H. Schott, L. C. Kwan, and S. Feldman. The role of surfactant in the release of very slightly soluble drugs from tablets. J. Pharm. Sci. 71:1038-1045 (1982).
11. F. Veiga, J. J. C. Teixeria-Dias, F. Kedzeierewicz, A. Sousa, and P. Maincent. Inclusion complexation of tolbutamide with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 129:63-71 (1996).
12. J. O. Henck, U. J. Griesser, and A. Burger. Polymorphie von Arzneistoffen. Eine wirtschaftliche Herausforderung? Pharm. Ind. 59:165-169 (1997).
13. B. C. Hancock, and G. Zografi. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86:1-12 (1997).
14. W. L. Chiou, and S. Riegelman. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60:1281-1302 (1971).
15. L. Christian, and J. Dressman. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50:47-60 (2000).
16. A. T. M. Serajuddin. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88:1058-1066 (1999).
17. D. Q. M. Craig. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm. 231:131-144 (2002).
18. N. Zajc, A. Obreza, M. Bele, and S. Srcic. Physical properties and dissolution behavior of nifedipine/mannitol solid dispersions prepared by hot melt method. Int. J. Pharm. 291:51-58 (2005).
19. L. Wang, F. D. Cui, and H. Sunada. Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method. Chem. Pharm. Bull. 54:37-43 (2006).
20. V. Tantishaiyakul, N. Kaewnopparat, and S. Ingkatawornwong. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int. J. Pharm. 181:143-151 (1999).
21. I. Weuts, D. Kempen, G. Verreck, A. Decorte, K. Heymans, J. Peeters, M. Brewster, and G. V. Mooter. Study of the physicochemical properties and stability of solid dispersions of loperamide and PEG 6000 prepared by spray drying. Eur. J. Pharm. Biopharm. 59:119-126 (2005).
22. M. Adel El-Egakey, M. Soliva, and P. Speiser. Hot extruded dosage forms. Pharm. Acta Helv. 46: 31-52 (1971).
23. S. Dastmalchi, A. Garjani, N. Maleki, G. Sheikhee, V. Baghchevan, P. Jafari-Azad, H. Valizadeh, and M. Barzegar-Jalali. Enhancing dissolution, serum concentrations and hypoglycemic effect of glibenclamide using solvent deposition technique. J. Pharm. Pharm. Sci. 8: 175-181 (2005).
24. E. J. Kim, M. K. Chun, and J. S. Jang. Preparation of a solid dispersion of felodipine using a solvent wetting method. Eur. J. Pharm. Biopharm. 64: 200-205 (2006).
25. U.S. Food and drug administration. Dissolution methods for drug products Website. Available at: http://www.accessdata.fda.gov/scripts/cder/ dissolution/dsp_SearchResults_Dissolutions.cfm?PrintAll=1. Accessed January 24, 2007.
26. K. Busaranon, W. Suntornsuk, and L. Suntornsuk. Comparison of UV spectrophotometric method and high performance liquid chromatography for the analysis of flunarizine and its application for the dissolution test. J. Pharm. Biomed. Anal. 41: 158-164 (2006).
27. J. A. Ryan. Compressed pellet X-ray diffraction monitoring for optimisation of crystallinity in lyophilised solids: Imipenem: cilastatin sodium case. J. Pharm. Sci. 75: 805-807 (1986).
28. O. I. Corrigan, E. M. Holohan, and M. R. Reilly. Physicochemical properties of indomethacin and related compound co-spray dried with polyvinyl pyrrolidone. Drug Dev. Ind. Pharm. 11: 677-695 (1985).
29. A. S. Geneidi, A. A. Ali, and R. B. Salama. Solid dispersions of nitrofurantoin, ethotoin and coumarin with polyethylene glycol 6000 and other coprecipitates with povidone 25000. J. Pharm. Sci. 67: 114-116 (1978).
30. T. Save, and P. Venkitachalam. Studies on solid dispersions of nifedipine. Drug Dev. Ind. Pharm. 18: 1663-1679 (1992).
31. J. L. Ford. The current status of solid dispersions. Pharm. Acta Helv. 61: 69-88 (1986).
32. K. A. Khan. The concept of dissolution efficiency. J. Pharm. Pharmacol. 27: 48-49 (1975).
33. N. H. Anderson, M. Bauer, N. Boussac, R. Khan-Malek, P. Munden, and M. Sardaro. An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles. J. Pharm. Biomed. Anal. 17: 811-822 (1998).